Thera-SAbDab

GUSELKUMAB

>   Structural Summary
TherapeuticGuselkumab
TargetIL23A
Heavy ChainEVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPSNSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSS
Light ChainQSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCASWTDGLSLVVFGGGTKLTVL
100% seqID Fv Structure4m6m [Fvs: HL], 4m6n [Fvs: HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental TechnologyMorphoSys HuCAL Phage Display
INN Year Proposed2013
INN Year Recommended2014
Companies InvolvedJanssen Biotech, MorphoSys, Taiho Pharmaceutical
Conditions ApprovedErythrodermic psoriasis, Palmoplantar pustulosis, Plaque psoriasis, Psoriatic arthritis, Pustular psoriasis
Conditions ActiveCrohn's disease, Hidradenitis suppurativa, Rheumatoid arthritis, Ulcerative colitis, Familial adenomatous polyposis
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]